Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

Jake Leach, President and CEO of Dexcom

“Publication of CONNECT in The New England Journal of Medicine represents a significant moment for the CGM category. Nearly two decades after NEJM last published clinical data on real-time CGM, we now have compelling evidence demonstrating the impact this technology can have for the millions of people with Type 2 diabetes who are not using insulin”

Jake Leach, President and CEO of Dexcom

“Dexcom has spent more than 25 years building the CGM category, and today the evidence is undeniable. We’re calling on physicians, payors and healthcare leaders to recognize the meaningful impact CGM can have for this population and help bring the benefits of this technology to millions more people around the world.”

Roy W. Beck, MD, PhD, Medical Director of the JAEB Center for Health Research and senior author of the study

“These results provide compelling evidence that CGM use can meaningfully improve glucose outcomes for people with Type 2 diabetes who are not using insulin”

Roy W. Beck, MD, PhD, Medical Director of the JAEB Center for Health Research and senior author of the study

“The fact that almost all participants were still using CGM after 26 weeks and most were using it every day indicates that the participants recognized the benefit of CGM and incorporated it into their daily diabetes management. Furthermore, the consistency of benefit across a broad range of people and treatment regimens supports consideration of the use of a CGM much earlier in Type 2 diabetes management before insulin is needed.”